Big pharma’s insatiable appetite for assets and dealmaking by small and mid-sized companies is ramping up in 2026. China continues to grow as a global R&D player, with many companies increasingly looking for best-in-class assets.
Big pharma’s insatiable appetite for assets and dealmaking by small and mid-sized companies is ramping up in 2026. China continues to grow as a global R&D player, with many companies increasingly looking for best-in-class assets.